Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Acquire Syn X Pharma in CA$16.3M Transaction

NEW YORK, Feb. 10 (GenomeWeb News) - Nanogen plans to acquire Syn X Pharma in an all-stock transaction, the company said today.

 

The transaction is valued at approximately CA$16.3 million ($12.3 million). Under the agreement, Nanogen will offer common shares to holders of Syn X common shares in a stock-for-stock exchange.

 

Nanogen, based in San Diego, plans to operate Toronto-based Syn X as a business unit under its current name and retain the company's research facility. Syn X managers George Jackowski and Rod Wilson are to join Nanogen's management team. Nanogen said the acquisition will help it expand its share in the in vitro diagnostics market. The company expects the Syn X unit to be cash flow positive by the end of 2005.

 

The acquisition, unanimously approved by Syn X directors, is subject to Syn X shareholder approval and other conditions. Nanogen expects the deal to close by the end of June.

 

Click here for further information from Nanogen.

 

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.